Table 4.

Timing of DAA therapy initiation in patients with HCC, stratified by HCC treatment (n=279)

Provider practice	N (%)
Timing of DAA initiation in patient with BCLC stage A HCC undergoing surgical resection
Shortly after resection (prior to imaging showing CR)	52 (18.8)
<3 months after CR	84 (30.3)
3–6 months after CR	41 (14.8)
6–12 months after CR	86 (31.1)
>12 months after CR	14 (5.0)
Timing of DAA in patient with BCLC stage B HCC undergoing TACE
Shortly after TACE (prior to imaging showing CR)	47 (17.2)
<3 months after CR	68 (24.8)
3–6 months after CR	41 (15.0)
6–12 months after CR	87 (31.7)
>12 months after CR	31 (11.3)
Timing of DAA in patient with BCLC stage C HCC undergoing systemic therapy	27 (9.8)
Begin DAA at time of initiating systemic therapy	34 (12.4)
Start DAA if partial response	78 (28.4)
Start DAA if complete response	19 (6.9)
Would start DAA if develops liver dysfunction, even if active HCC	117 (42.5)
Would never start DAA
Timing of DAA therapy in liver transplant candidate with HCC
Routinely treat pre-transplant on waitlist	15 (5.5)
Case-by-case basis	115 (42.0)
Routinely treat with DAA within 3 months post-transplant	118 (43.0)
Routinely defer DAA > 6 months post-transplant	26 (9.5)

DAA – direct-acting antiviral; CR – complete response; HCC – hepatocellular carcinoma; BCLC – Barcelona Clinic Liver Cancer